<DOC>
	<DOCNO>NCT00544362</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Radiation therapy use high-energy x-ray kill tumor cell . Giving fluorouracil cisplatin together cetuximab radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose fluorouracil cisplatin give together cetuximab radiation therapy treat patient esophageal cancer remove surgery .</brief_summary>
	<brief_title>Fluorouracil , Cisplatin , Cetuximab , Radiation Therapy Treating Patients With Esophageal Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose fluorouracil cisplatin administer cetuximab concurrently esophageal radiotherapy . ( Phase I ) - To determine complete histological response rate ( surgical resection ) . ( Phase II ) Secondary - To determine progression-free survival overall survival . ( Phase II ) - To determine rate resection negative margin ( R0 ) . ( Phase II ) - To determine overall tolerance neoadjuvant therapy . ( Phase II ) - To determine postoperative morbidity mortality . ( Phase II ) OUTLINE : This multicenter study . This dose-escalation study cisplatin fluorouracil . Patients receive cetuximab IV 2 hour day -7 , IV 1 hour day 1 , 8 , 15 , 22 , 29 . Patients also receive cisplatin IV 1 hour day 1 2 fluorouracil IV continuously day 1-4 , 8-11 , 15-18 , 22-25 , 29-32 . Patients undergo radiotherapy 5 day week 5 week , begin day 1 chemotherapy . Treatment continue absence disease progression unacceptable toxicity . Patients undergo surgery within 6-8 week completion chemoradiotherapy . After completion study therapy , patient follow 1 month , every 4 month 2 year , every 6 month 2 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically confirm epidermoid glandular carcinoma thoracic esophagus Invasive disease Only Siewert type I gastroesophageal carcinoma allow Resectable disease T1N+ , T2N0 , T2N+ , T3N0 , T3N+ ( stage II III ) No visceral metastasis mediastinal extension compromise resectability Exclusion criterion : Inoperable disease Invasion tracheobronchial tree Recurring esophageal paralysis Esophotracheal fistula Cervical esophageal carcinoma ( &lt; 19 cm dental arch ) Multifocal esophageal carcinoma Superficial esophageal carcinoma ( T1N0 ) Esophageal carcinoma lymph node include radiotherapy field completely surgically resect Proven metastatic disease PATIENT CHARACTERISTICS : Inclusion criterion : WHO performance status 01 Weight loss &lt; 15 % Absolute neutrophil count ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Creatinine ≤ 1.25 time upper limit normal PTT ≥ 80 % Albumin ≥ 35 g/L FEV1 &gt; 1 L Not pregnant nursing Fertile patient must use effective contraception Exclusion criterion : Known liver cirrhosis Renal insufficiency Respiratory insufficiency ( i.e. , severe dyspnea rest oxygen dependence ) Progressive coronary insufficiency Myocardial infarction past 6 month Legally incapacitate Impossible receive study therapy due geographical , social , psychological reason Noncompliant within constraint study Hematologic malignancy cancer except carcinoma situ uterine cervix , treat nonmelanoma skin cancer , intramucous disease treat within past 3 year PRIOR CONCURRENT THERAPY : Exclusion criterion : Prior anticancer chemotherapy radiotherapy Treatment endoprosthesis Surgery ( esophagectomy ) plan without thoracotomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>